A report from Accenture, based on interviews with 75 R&D execs from large biopharma companies, found adopting the technology could cut costs by up to 45%.

The venture capital firm announced a $3.6bn raise for Fund VIII and side funds, which it plans to invest across human health, AI and sustainability-focused companies.

The difficult investment environment has made it harder to build newcos, but panelists at the Galien Forum talked about how that might help limit some of the me-too companies that proliferate when financing is easier.

Private Company Edition: Quarter-over-quarter increases in venture capital have been bolstered by fewer but larger rounds, like the recent $245m series A for Aiolos. Also, OrbiMed raised $4.3bn across three new VC funds, Rampart completed an $85m series A and Atom Bioscience raised an $83m series D.